DrugPatentWatch Database Preview

Details for Patent: 8,143,212

« Back to Dashboard

Which drugs does patent 8,143,212 protect, and when does it expire?

Patent 8,143,212 protects DALVANCE and is included in one NDA.

This patent has fifty-three patent family members in sixteen countries.

Summary for Patent: 8,143,212

Title:	Dalbavancin compositions for treatment of bacterial infections
Abstract:	The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A.sub.0, A.sub.1, B.sub.1, B.sub.2, C.sub.0, C.sub.1, isoB.sub.0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included.
Inventor(s):	Stogniew; Martin (Blue Bell, PA), Colombo; Luigi (Malnate, IT), Ciabatti; Romeo (Novate Milanese, IT)
Assignee:	Vicuron Pharmaceuticals Inc. (Morristown, NJ)
Application Number:	12/476,785
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,143,212

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Allergan Sales Llc	DALVANCE	dalbavancin hydrochloride	POWDER;IV (INFUSION)	021883-001	May 23, 2014		RX	Yes	Yes						TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

Non-Orange Book US Patents Family Members for Patent 8,143,212

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,119,061	Dalbavancin compositions for treatment of bacterial infections
6,900,175	Methods of administering dalbavancin for treatment of bacterial infections
7,115,564	Stable pharmaceutical compositions of dalbavancin and methods of administration

International Patents Family Members for US Patent 8,143,212

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Israel	230875
Israel	239913
Japan	2007534768
Japan	5207734